E.g., 09/28/2020
E.g., 09/28/2020

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

04 May, 2020

BioFire Diagnostics, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease).

bioMérieux – First-Quarter 2020 Business Review

16 April, 2020

Marcy l'Étoile (France), April 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, released its business review for the three months ended March 31, 2020.

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

BioFire Defense, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical laboratories to detect SARS-CoV-2.

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

11 March, 2020

bioMérieux has finalized the development of the SARS-COV-2 R-GENE® test. This realtime PCR test is clinically validated on one type of respiratory specimen and will be available at the end of March.

Holiday Shipping Schedule

09 January, 2020

Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Monday, January 20, 2020 in observance of Martin Luther King Jr. Day. 

bioMérieux and The Fleming Fund: Working Together to Tackle Antimicrobial Resistance

18 December, 2019

Our partnership with the Fleming Fund will seek to strengthen antimicrobial resistance survillance systems and improve public awareness of AMR in -low and -middle-income countries.

Holiday Shipping Schedule

04 December, 2019

Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on December 24 - 25, 2019 and January 1, 2020 in observance of the upcoming holidays. 

Triangle Business Journal Highlights Impact of new CMS Rules on AMR, Hospitals, and bioMérieux

20 November, 2019

An article, published on November 15, 2019 in the Triangle Business Journal, discussed the impact of the new Centers for Medicare and Medicaid Services (CMS) Rules on antimicrobial resistance, hospital antimicrobial stewardship programs, and bioMérieux, Inc.

Pioneering Diagnostics